US20030139382A1 - Method of treating middle ear infections - Google Patents
Method of treating middle ear infections Download PDFInfo
- Publication number
- US20030139382A1 US20030139382A1 US10/243,341 US24334102A US2003139382A1 US 20030139382 A1 US20030139382 A1 US 20030139382A1 US 24334102 A US24334102 A US 24334102A US 2003139382 A1 US2003139382 A1 US 2003139382A1
- Authority
- US
- United States
- Prior art keywords
- dexamethasone
- ciprofloxacin
- ciprodex
- ear
- aqueous suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000022760 infectious otitis media Diseases 0.000 title claims abstract description 23
- 206010033078 Otitis media Diseases 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 22
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 76
- 239000000203 mixture Substances 0.000 claims abstract description 47
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 28
- 229960003405 ciprofloxacin Drugs 0.000 claims abstract description 25
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 21
- 210000003454 tympanic membrane Anatomy 0.000 claims abstract description 21
- 239000007900 aqueous suspension Substances 0.000 claims abstract description 13
- NTRHYMXQWWPZDD-WKSAPEMMSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NTRHYMXQWWPZDD-WKSAPEMMSA-N 0.000 claims description 96
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 11
- 229960004224 tyloxapol Drugs 0.000 claims description 11
- 229920001664 tyloxapol Polymers 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 7
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 7
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 5
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 5
- 239000004327 boric acid Substances 0.000 claims description 5
- 229940124274 edetate disodium Drugs 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 239000012929 tonicity agent Substances 0.000 claims description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 4
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 claims description 4
- 150000004682 monohydrates Chemical class 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 4
- 241000746998 Tragus Species 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 210000000613 ear canal Anatomy 0.000 claims description 3
- 210000000959 ear middle Anatomy 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 47
- 238000009472 formulation Methods 0.000 abstract description 32
- 229940021285 ciprodex Drugs 0.000 description 74
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical group FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 51
- 229940072686 floxin Drugs 0.000 description 43
- 206010033101 Otorrhoea Diseases 0.000 description 41
- 229940088515 ciloxan Drugs 0.000 description 26
- 230000004044 response Effects 0.000 description 20
- 208000026231 acute otitis externa Diseases 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 16
- 230000002906 microbiologic effect Effects 0.000 description 14
- 230000000699 topical effect Effects 0.000 description 14
- 239000000725 suspension Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 230000002411 adverse Effects 0.000 description 11
- 230000008029 eradication Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229940111645 cortisporin Drugs 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 108010060832 polymyxin B drug combination neomycin hydrocortisone Proteins 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010014020 Ear pain Diseases 0.000 description 7
- 229940045716 ciprofloxacin / dexamethasone Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 206010063560 Excessive granulation tissue Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000012076 audiometry Methods 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 229940127555 combination product Drugs 0.000 description 6
- 239000013066 combination product Substances 0.000 description 6
- 210000001126 granulation tissue Anatomy 0.000 description 6
- -1 quaternary ammonium halide Chemical class 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 206010066901 Treatment failure Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 229960001699 ofloxacin Drugs 0.000 description 4
- 229940127249 oral antibiotic Drugs 0.000 description 4
- 229940100683 otic suspension Drugs 0.000 description 4
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229940098164 augmentin Drugs 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960001716 benzalkonium Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000010338 boric acid Nutrition 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 229940088516 cipro Drugs 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 229940100685 otic solution Drugs 0.000 description 2
- 206010033072 otitis externa Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940127559 single-entity product Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- QJVHTELASVOWBE-AGNWQMPPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010007356 Sofradex Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001147693 Staphylococcus sp. Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- DPHFJXVKASDMBW-RQRKFSSASA-N [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;hydrate Chemical compound O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O DPHFJXVKASDMBW-RQRKFSSASA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960003704 framycetin Drugs 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940035274 tobradex Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the use of formulations of ciprofloxacin and dexamethasone to treat otic infections. Specifically, the invention relates to the topical use of such a fixed combination to treat middle ear infections in humans.
- External ear infections known as acute otitis externa (“AOE”)
- AOE acute otitis externa
- An example of an oral antibiotic product used to treat AOE is AUGMENTIN® (amoxicillin and clavulanic acid).
- An example of a single-entity antibiotic product approved for topical use in treating AOE is FLOXIN® (ofloxacin).
- Examples of combination products approved for this use include CORTISPORIN® (hydrocortisone, neomyciri sulfate, and polymyxin b sulfate) and CIPRO®HC (ciprofloxacin and hydrocortisone).
- SOFRADEX gramicidin, framycetin and hydrocortisone
- SOFRADEX gramicidin, framycetin and hydrocortisone
- External ear infections typically involve bacteria of the following types: Pseudomonas aeruginosa, Staphylococcus aureus. Staphylococcus sp. and Coryneforms.
- middle ear infections known as otitis media (“OM”) typically involve bacteria of the following types: S. pneumonia, H. influenzae and M. catarrhalis.
- Patients with chronic or severe middle ear infections may have their ear drums (tympanic membranes) intentionally punctured and drainage tubes, often referred to as a tympanostomy tubes, implanted.
- tympanic membranes may rupture.
- open tympanic membranes allow the bacteria characteristic of AOE and OM to mix.
- the present invention provides a method of topically treating OM in human patients who have open tympanic membranes.
- the method involves the topical application of a fixed combination of ciprofloxacin and dexamethasone as an aqueous suspension product.
- the dosing regimen may vary depending on the age and weight of the patient, as well as the severity of the infection, in most cases, the combination product would be applied twice a day.
- Each application would involve topically administering three or four drops into the ear canal, preferably pumping the tragus to force product through the opening in the tympanic membrane and to the site of the infection/inflammation in the middle ear.
- the present invention is based on the finding that an aqueous combination of ciprofloxacin and dexamethasone was not statistically more effective than ciprofloxacin alone in the treatment of AOE, but was surprisingly statistically more effective that ciprofloxacin alone in the treatment of OM in patients with an open tympanic membrane.
- FIG. 1 shows the average number of days to time of cessation of ear pain in a human clinical study comparing a ciprofloxacin/dexamethasone combination product to a ciprofloxacin single-entity product.
- FIG. 2 shows the average number of days to cessation of otorrhea in a human clinical study comparing a ciprofloxacin/dexamethasone combination product to a ciprofloxacin single-entity product.
- the methods of the present invention involve diagnosing a human patient as having OM and an open tympanic membrane.
- Open tympanic membrane means that the membrane has been intentionally punctured, with or without tympanostomy tube implantation, or has accidentally ruptured.
- the method of the present invention involves topically administering to the ear canal of the patient's affected ear an aqueous suspension formulation of a fixed combination of ciprofloxacin and dexamethasone.
- OM includes, but is not limited to, acute otitis media and chronic supprative otitis media.
- Dexamethasone can be present in any ophthalmically or otically acceptable form having poor water solubility such that the resulting formulation is a suspension formulation. Suitable forms of dexamethasone include dexamethasone alcohol (alcohol form of dexamethasone), dexamethasone acetate and dexamethasone phosphate. Dexamethasone alcohol is the preferred form of dexamethasone.
- the average particle size (mean volume basis) of the dexamethasone ingredient should be less than 10 ⁇ m to avoid irritation or discomfort The average particle size is preferably less than 6 ⁇ m and most preferably less than 3 ⁇ m.
- Dexamethasone particles can be sized using known techniques, such as ball-milling, microfluidization and sonication.
- the ciprofloxacin ingredient can be any otically acceptable form such that the ciprofloxacin ingredient is in solution in the final formulation.
- a preferred form of ciprofloxacin is ciprofloxacin hydrochloride, monohydrate.
- the dexamethasone ingredient will comprise about 0.01-0.5% and the ciprofloxacin ingredient will comprise about 0.1-0.4% of the aqueous suspension formulations administered according to the present invention.
- the preferred amounts of dexamethasone and ciprofloxacin in the formulations used in the present invention are 0.1% and 0.3%, respectively.
- the suspension formulations used in the present invention contain a tonicity agent.
- the tonicity agent may be ionic (e.g., NaCl) or nonionic (e.g., mannitol).
- the tonicity agent is preferably NaCl.
- the amount of NaCl will depend on the desired tonicity for the final formulation, but will generally range from 0.1-0.9%.
- the suspension formulations of the present invention preferably contain an amount of tonicity agent sufficient to cause the formulations to have an osmolality of about 250-350 mOsm.
- the suspension formulations also contain a nonionic polymer as a suspending agent.
- a nonionic polymer as a suspending agent.
- Many otically acceptable nonionic polymers are known. These polymers include hydroxyethyl cellulose; hydroxypropylmethyl cellulose; methyl cellulose; carboxymethyl cellulose; polyvinyl pyrrolidone and polyvinyl alcohol.
- the preferred nonionic polymer is hydroxyethyl cellulose.
- the nonionic polymer will be present in the formulations of the present invention in an amount of about 0.1-0.5%. In the case of hydroxyethyl cellulose, the preferred concentration of nonionic polymer is 0.2%.
- the formulations of the present invention also contain a nonionic surfactant in an amount from about 0.01-0.2%.
- a nonionic surfactant in an amount from about 0.01-0.2%.
- Suitable nonionic surfactants include tyloxapol; polyoxyethylene sorbitan esters, such as polysorbate 20, polysorbate 60, and polysorbate 80; polyethoxylated castor oils, such as Cremaphor EL; polyethoxylated hydrogenated castor oils, such as HCO-40; and poloxamers.
- the preferred surfactant is tyloxapol.
- the formulations may contain a quaternary ammonium halide as a preservative.
- Suitable quaternary ammonium halides include polyquaternium-1 and benzalkonium halides.
- Preferred benzalkonium halides are benzalkonium chloride (“BAC”) and benzalkonium bromide.
- BAC benzalkonium chloride
- the amount of the preservative ingredient will range from about 0.005-0.3%. In the preferred case where the preservative is BAC, it is preferably present at a concentration of 0.01%.
- a chelating agent may also be present in the suspension formulations used in the methods of the present invention.
- Suitable chelating agents include edetate disodium (“EDTA”); edetate trisodium; edetate tetrasodium; and diethyleneamine pentaacetate. Most preferred is EDTA.
- the chelating agent if any, will typically be present in an amount from about 0.001-0.1%. In the case of EDTA, the chelating agent is preferably present at a concentration of 0.01%.
- the suspension formulations of the present invention may contain boric acid in an amount from 0.1-1.5%.
- the formulations administered according to the present invention have a pH from 3-6, preferably 4.5. pH can be adjusted with NaOH/HCl.
- the preferred buffering system for these formulations is a combination of sodium acetate and acetic acid.
- the concentration of sodium acetate will generally range from 0.015-0.06%, and will preferably be about 0.03%.
- the concentration of acetic acid will generally range from 0.02-0.08, and will preferably be about 0.04%.
- the ciprofloxacin/dexamethasone combination products administered according to the present invention will generally be administered twice a day.
- Each administration will typically involve placing 3-4 drops (with a typical drop volume of 30-35 ⁇ L) of the suspension product in the affected ear.
- the patient will pump the tragus of the affected ear to force the administered product through the opening in the tympanic membrane and to the site of the infection/inflammation in the middle ear.
- the present invention relates to a ciprofloxacin/dexamethasone aqueous suspension composition that is packaged with directions for use that indicate the composition may be used to treat otitis media in patients with an open tympanic membrane.
- directions for use includes information contained in product labeling, package inserts and cartons or other packaging materials that accompany the ciprofloxacin/dexamethasone aqueous suspension composition of the present invention.
- a B C D E Ingredients % (w/w) % (w/w) % (w/w) % (w/w) % (w/w) % (w/w) Ciprofloxacin HCl, 0.35* 0.35 0.35 0.35 0.35 0.35 Monohydrate Dexamethasone Alcohol 0.1 0.1 0.1 0.1 0.1 Hydroxyethyl Cellulose 0.2 0.2 0.2 0.2 0.2 Benzalkonium Chloride 0.01 0.01 0.01 0.01 0.01 0.01 Sodium Acetate (Trihydrate) 0.03 0.03 0.03 0.03 0.03 0.03 Acetic Acid 0.04 0.04 0.04 0.04 0.04 Sodium Chloride 0.25 0.25 0.80 0.53 — Edetate Disodium 0.01 0.01 0.01 0.01 0.01 0.01 0.01 Tyloxapol 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 Glycerin 1.5 — — — 2.35 Boric Acid — — — 0.6 — NaOH/HCl
- (4) prepare an aqueous solution containing the remaining requirement of tyloxapol and the required amounts of all remaining ingredients (e.g., in the case of Formulation D, the remaining ingredients are ciprofloxacin hydrochloride monohydrate, benzalkonium chloride, sodium acetate, acetic acid, sodium chloride, hydroxyethylcellulose, boric acid, edetate disodium, and purified water;
- the remaining ingredients are ciprofloxacin hydrochloride monohydrate, benzalkonium chloride, sodium acetate, acetic acid, sodium chloride, hydroxyethylcellulose, boric acid, edetate disodium, and purified water;
- (6) combine the sterile slurry obtained in step 3 to the sterile solution obtained in step 5 by aseptically pouring the slurry through a sterile sieve (to remove the beads) into the solution obtained in step 5;
- (5) prepare an aqueous solution containing the required amounts of the remaining ingredients (e.g., in the case of Formulation D, the remaining ingredients are ciprofloxacin hydrochloride, monohydrate benzalkonium chloride, sodium acetate, acetic acid, sodium chloride, hydroxyethylcellulose, boric acid, edetate disodium and purified water;
- the remaining ingredients are ciprofloxacin hydrochloride, monohydrate benzalkonium chloride, sodium acetate, acetic acid, sodium chloride, hydroxyethylcellulose, boric acid, edetate disodium and purified water;
- a clinical study with a primary objective of demonstrating superiority of a ciprofloxacin/dexamethasone combination product (“ciprofloxacin 0.3%, dexamethasone 0.1%; Formulation D above) (“CIPRODEX”) relative to the marketed CILOXAN® single-agent (ciprofloxacin 0.3%; Alcon Laboratories, Inc.) product for time to cessation of ear pain in patients with moderate to severe acute otitis externa (AOE) was conducted.
- a summary of the study details for this AOE study is provided below. Summary of AOE Study CIPRODEX (Ciprofloxacin 0.3%) Suspension vs.
- CILOXAN (Ciprofloxacin 0.3%) Solution vs. CORTISPORIN Suspension (Neomycin 0.35%, Polymyxin B 10,000 IU/mL, Hydrocortisone 1.0%) for Topical Treatment of patients with moderate to severe Acute Otitis Externa (AOE).
- Study Design Phase III multicenter, randomized, single-blind, active controlled, parallel group study. Study Primary objectives of the study were to demonstrate: Objectives: Superiority of CIPRODEX combination relative to CILOXAN single agent for time to cessation of ear pain. Therapeutic non-inferiority of CIPRODEX combination relative to CILOXAN single agent based on clinical response at the test of cure (TOC) visit (Day 18).
- Study Visits Day 1, Day 3, Day 8 (End of Therapy, EOT), and Day 18 (TOC).
- Evaluation Physician evaluation of signs and symptoms of AOE, including inflammation, tenderness, edema, and otic discharge by visit.
- Microbiology Microbiology outcomes were based on presumed or confirmed bacterial eradication.
- Efficacy Cessation of ear pain was defined as the first day where the patient dairy Criteria: pain score was zero, with no analgesics used in the prior 24 hours, and the ear pain score remained zero for all subsequent entries.
- CILOXAN treatments i.e., no contribution of elements.
- CIPRODEX is non-inferior to CILOXAN for clinical cures and microbiological eradication.
- CIPRODEX produces more clinical cures than CORTISPORIN and is non-inferior for microbiological eradication.
- CILOXAN is superior to CORTISPORIN for clinical response in culture positive patients, and non-inferior for microbial eradication.
- CIPRODEX and CILOXAN are safe and well tolerated in pediatric and adult patients with AOE.
- Study Visits Day 1, Day 3, Day 8 (End of Therapy, EOT), and Day 14 (Test of Cure, TOC).
- Physician evaluation of signs and symptoms of AOMT including presence of otorrhea, characteristics of otorrhea, presence of granulation tissue, tube patency, and overall clinical response by visit.
- Microbiology Microbiology outcomes were based on presumed or confirmed bacterial eradication.
- CIPRODEX is statistically significantly more effective than CILOXAN for Physician's Clinical Impression at the Day 3 Visit, but not at the Day 8 or Day 14 Visits (using Cochran-Mantel-Haenszel Rank Scores Test). No statistically significant differences were detected between CIPRODEX and CILOXAN for Microbiological Eradication Rates at the Test of Cure Visit (using Fisher's Exact Test). CIPRODEX and CILOXAN are safe and well tolerated in pediatric with AOMT.
- the results of this study for the MITT population are presented in Table 2 and FIG. 2.
- the MITT population is defined as the population that received study drug, met inclusion criteria, participated in at least one on-therapy visit, and was culture positive for bacteria on Day 1.
- the MITT population for this study comprised 87 patients for CIPRODEX and 80 patients for CILOXAN.
- Study Design Phase III, randomized, evaluator-masked, active-controlled, parallel-group study.
- Patient Population Approximately 500 pediatric patients with AOMT and post-tympanostomy tube otorrhea (250/arm) were planned. A total of 599 patients were enrolled.
- Duration of Treatment Patients were required to undergo treatment for either seven (7) days if randomized to receive CIPRODEX or ten (10) days if randomized to receive FLOXIN.
- Criteria for Evaluation Subsequent to the demonstration of non-inferiority, superiority analyses were conducted. Analyses for the determination of superiority were based on the data set of patients who received treatment, had a positive pre-therapy culture and met the inclusion/exclusion criteria for enrollment (modified intent-to-treat, MITT). Analyses were also conducted for the intent-to-treat (ITT), per protocol (PP) and modified per protocol (MPP) data sets.
- ITT intent-to-treat
- PP per protocol
- MPP modified per protocol
- Safety The safety evaluation was conducted on all patients who were randomized into the study and received at least one dose of study drug. The safety analysis was based on the following; extent of exposure to study drug; adverse events; and audiometry examination.
- CIPRODEX Otic Suspension is superior to FLOXIN Otic Solution in clinical and microbiological response at the test of cure (TOC) visit;
- CIPRODEX Otic Suspension is effective and safe for the treatment of pediatric patients with acute otitis media and otorrhea with tympanosotomy tubes (AOMT).
- AOMT tympanosotomy tubes
- CIPRODEX was superior to FLOXIN for treatment failure rate (p ⁇ 0.0189).
- CIPRODEX was superior to FLOXIN for time to cessation of otorrhea for all data sets (p ⁇ 0.018). Clinically, this translates to the cessation of otorrhea in 20 to 33% less time for the CIPRODEX treated patients in comparison to the FLOXIN treated patients (median time of 4 days for CIPRODEX versus 5-6 days for FLOXIN).
- CIPRODEX is effective in treating acute otitis media with otorrhea in tympanostomy (AOMT) patients and results in 90% patients with clinical cure, 92% patients with microbiological success and a 4-day median time to cessation of otorrhea.
- CIPRODEX is superior to FLOXIN for clinical cures at the TOC visit.
- Clinical Cure Rates and 95% Confidence Intervals by Treatment Group (All Data Sets) Treatment CIPRODEX FLOXIN Clinical Cure Clinical Cure No Yes No Yes Data Set N % N % N % N % Delta Lower Upper P-value a ITT 75 25.25 222 74.75 117 38.74 185 61.26 13.49 6.10 20.88 0.0004 MITT 43 20.67 165 79.33 78 36.11 138 63.89 15.44 6.99 23.88 0.0004 PP 28 12.07 204 87.93 50 22.73 170 77.27 10.66 3.71 17.60 0.0027 MPP 18 10.00 162 90.00 37 21.76 133 78.24 11.76 4.17 19.36 0.0025
- CIPRODEX is superior to FLOXIN for microbiological eradication at the TOC visit.
- Treatment CIPRODEX FLOXIN Microbiological Microbiological Eradication Eradication Failure Success Failure Success Data Set N % N % N % N % Delta Lower Upper P-value a ITT 128 43.10 169 56.90 154 50.99 148 49.01 7.90 ⁇ 0.07 15.87 0.0529 MITT 41 19.71 167 80.29 72 33.33 144 66.67 13.62 5.33 21.91 0.0015 PP 67 28.88 165 71.12 81 36.82 139 63.18 7.94 ⁇ 0.70 16.58 0.0722 MPP 15 8.33 165 91.67 31 18.24 139 81.76 9.90 2.83 16.97 0.0061
- CIPRODEX is superior to FLOXIN for treatment failure rate. Discontinuations Due to Treatment Failure by Treatment Group Treatment CIPRODEX FLOXIN Treatment Failure Treatment Failure No Yes No Yes Data Set N % N % N % N % P-value ITT 281 94.61 16 5.39 270 89.40 32 10.60 0.0189 MITT 199 95.67 9 4.33 192 88.89 24 11.11 0.0091 PP 220 94.83 12 5.17 188 85.45 32 14.55 0.0008 MPP 172 95.56 8 4.44 146 85.88 24 14.12 0.0017
- CIPRODEX is superior to FLOXIN for improvement in clinical response at Days 3, 11 and 18.
- Clinical Response by Treatment Group (MITT) Treatment CIPRODEX FLOXIN Visit Clinical Response N % N % P-value a Day 3 Missing 1 0 0 0 ⁇ .000 1 Cured 64 30.92 38 17.59 Improved 130 62.80 134 62.04 Unchanged 9 4.35 35 16.20 Worse 4 1.93 9 4.17 Day 11 Missing 1 0 0 0 ⁇ .0001 Cured 174 84.06 136 62.96 Improved 25 12.08 58 26.85 Unchanged 4 1.93 12 5.56 Worse 4 1.93 10 4.63 Day 18 Missing 1 0 0 0 0.0023 Cured 174 84.06 153 70.83 Improved 20 9.66 38 17.59 Unchanged 6 2.90 12 5.56 Worse 7 3.38 13 6.02
- CIPRODEX is superior to FLOXIN for time to cessation of otorrhea.
- Time to Cessation of Otorrhea by Treatment Group (MITT) Treatment CIPRODEX FLOXIN P-value a Mean 6.02 7.10 0.0204 Median 4.00 5.00 Std 4.87 4.68 N 208 216 Min 2 2 Max 21 21
- CIPRODEX is superior to FLOXIN for absence of otorrhea at Days 3, 11 and 18. Presence/Absence of Otorrhea by Treatment Group (MITT) Treatment CIPRODEX FLOXIN Visit Otorrhea N % N % P-value a Day 1 Present 208 100.00 216 100.00 Day 3 Absent 67 32.21 40 18.52 0.0012 Present 141 67.79 176 81.48 Day 11 Absent 176 84.62 137 63.43 ⁇ .0001 Present 32 15.38 79 36.57 Day 18 Missing 1 0 0 0 0.0004 Absent 176 85.02 153 70.83 Present 31 14.98 63 29.17
- CIPRODEX is superior to FLOXIN for reduction in granulation tissue at Days 11 and 18.
- Granulation Tissue by Treatment Group (MITT) Treatment CIPRODEX FLOXIN Visit Granulation Tissue N % N % P-value a Day 1 Absent 159 76.44 175 81.02 0.3449 Mild 30 14.42 21 9.72 Moderate 15 7.21 16 7.41 Severe 4 1.92 4 1.85 Day 3 Missing 1 0 0 0 0.3285 Absent 177 85.51 182 84.26 Mild 24 11.59 22 10.19 Moderate 6 2.90 10 4.63 Severe 0 0.00 2 0.93 Day 11 Missing 1 0 0 0 0.0086 Absent 198 95.65 186 86.11 Mild 8 3.86 22 10.19 Moderate 1 0.48 8 3.70 Day 18 Missing 1 0 0 0 0.0383 Absent 203 98.07 192 88.89 Mild 3 1.45 21 9.72 Moderate 1 0.48 3 1.39
- CIPRODEX is superior to FLOXIN for reduction in otorrhea volume at Days 3, 11 and 18.
- Volume by Treatment Group (MITT) Treatment CIPRODEX FLOXIN Visit Volume N % N % P-value a Day 1 Scant 17 8.17 14 6.48 0.3195 Moderate 104 50.00 99 45.83 Copious 87 41.83 103 47.69 Day 3 Missing 1 0 0 0 ⁇ .0001 Absent 66 31.88 39 18.06 Scant 98 47.34 84 38.89 Moderate 34 16.43 77 35.65 Copious 9 4.35 16 7.41 Day 11 Missing 1 0 0 0 ⁇ .0001 Absent 175 84.54 136 62.96 Scant 19 9.18 42 19.44 Moderate 7 3.38 26 12.04 Copious 6 2.90 12 5.56 Day 18 Missing 2 0 0 0 0.0003 Absent 175 84.95 153 70.83 Scant 14 6.80 21 9.72 Moderate 8 3.88 27 12.50 Copious 9 4.
- CIPRODEX is superior to FLOXIN for absence of otorrhea color and less purulent otorrhea at Day 3, and absence of otorrhea color and less mucoid otorrhea at Days 11 and 18.
- SRT mean change of speech reception threshold
- CIPRODEX administered twice daily in the affected ear(s) is safe and well tolerated in pediatric patients with acute otitis media with tympanostomy tubes, based upon a review of adverse events and an assessment of audiometry parameters.
- CIPRODEX administered twice daily in the affected ear(s) is safe and well tolerated in pediatric patients with acute otitis media with tympanostomy tubes, based upon a review of adverse events and an assessment of audiometry parameters.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
Description
- This application claims priority to U.S. Provisional Application, Serial No. 60/323,951, filed Sep. 21, 2001.
- This invention relates to the use of formulations of ciprofloxacin and dexamethasone to treat otic infections. Specifically, the invention relates to the topical use of such a fixed combination to treat middle ear infections in humans.
- External ear infections, known as acute otitis externa (“AOE”), are currently treated with oral antibiotics, topical single-entity antibiotics, or topical antibiotic/steroid combination products. An example of an oral antibiotic product used to treat AOE is AUGMENTIN® (amoxicillin and clavulanic acid). An example of a single-entity antibiotic product approved for topical use in treating AOE is FLOXIN® (ofloxacin). Examples of combination products approved for this use include CORTISPORIN® (hydrocortisone, neomyciri sulfate, and polymyxin b sulfate) and CIPRO®HC (ciprofloxacin and hydrocortisone). A product called SOFRADEX (gramicidin, framycetin and hydrocortisone) is available in some European countries and in Australia. External ear infections typically involve bacteria of the following types:Pseudomonas aeruginosa, Staphylococcus aureus. Staphylococcus sp. and Coryneforms.
- In contrast, middle ear infections known as otitis media (“OM”) typically involve bacteria of the following types:S. pneumonia, H. influenzae and M. catarrhalis. Patients with chronic or severe middle ear infections may have their ear drums (tympanic membranes) intentionally punctured and drainage tubes, often referred to as a tympanostomy tubes, implanted. In other cases, particularly in patients with severe OM, the tympanic membrane may rupture. Whether surgically punctured or accidentally ruptured, open tympanic membranes allow the bacteria characteristic of AOE and OM to mix.
- Patients with OM are currently treated with oral antibiotics such as AUGMENTIN® When drainage through an open tympanic membrane into the outer ear persists, either an oral antibiotic (e.g., AUGMENTIN®) or a topical antibiotic (e.g., FLOXIN®) is often prescribed. Additionally, topical antibiotic/steroid combination products approved for AOE have been used “off-label” in some cases to treat OM in patients with an open tympanic membrane, including CORTISPORIN®, CIPRO®HC, and TOBRADEX® (tobramycin and dexamethasone). To date, however, no topical antibiotic/steroid combination product has been approved by the Food and Drug Administration in the U.S. for the treatment of OM in patients with an open tympanic membrane.
- Fixed combination products containing ciprofloxacin and dexamethasone are known. Although no such product is currently approved in the U.S., this combination is commercially available for ophthalmic use in certain countries in South America as Biomotil-D (Allergan Frumtost) and Cilodex (Alcon Laboratories). Although the use of ciprofloxacin/dexamethasone combinations for the treatment of ocular and/or otic infections has been disclosed in the scientific and patent literature (see, for example, Spanish Patent Application No. 2,065,846 Al (Feb. 16, 1995), WO 90/01933 and U.S. Pat. No. 6,284,804), there has been no disclosure of the use of such a combination specifically for treating OM in patients with open tympanic membranes.
- The present invention provides a method of topically treating OM in human patients who have open tympanic membranes. The method involves the topical application of a fixed combination of ciprofloxacin and dexamethasone as an aqueous suspension product. Although the dosing regimen may vary depending on the age and weight of the patient, as well as the severity of the infection, in most cases, the combination product would be applied twice a day. Each application would involve topically administering three or four drops into the ear canal, preferably pumping the tragus to force product through the opening in the tympanic membrane and to the site of the infection/inflammation in the middle ear.
- Among other factors, the present invention is based on the finding that an aqueous combination of ciprofloxacin and dexamethasone was not statistically more effective than ciprofloxacin alone in the treatment of AOE, but was surprisingly statistically more effective that ciprofloxacin alone in the treatment of OM in patients with an open tympanic membrane. The fact that a contribution of elements for ciprofloxacin and dexamethasone could be demonstrated for only OM and not AOE was not predictable, nor was the fact that such a contribution of elements would be shown in OM.
- FIG. 1 shows the average number of days to time of cessation of ear pain in a human clinical study comparing a ciprofloxacin/dexamethasone combination product to a ciprofloxacin single-entity product.
- FIG. 2 shows the average number of days to cessation of otorrhea in a human clinical study comparing a ciprofloxacin/dexamethasone combination product to a ciprofloxacin single-entity product.
- Unless indicated otherwise, all ingredient amounts presented as a percentage are in units of weight %.
- The methods of the present invention involve diagnosing a human patient as having OM and an open tympanic membrane. “Open tympanic membrane” means that the membrane has been intentionally punctured, with or without tympanostomy tube implantation, or has accidentally ruptured. Once diagnosed with OM and an open tympanic membrane, the method of the present invention involves topically administering to the ear canal of the patient's affected ear an aqueous suspension formulation of a fixed combination of ciprofloxacin and dexamethasone. OM includes, but is not limited to, acute otitis media and chronic supprative otitis media.
- Dexamethasone can be present in any ophthalmically or otically acceptable form having poor water solubility such that the resulting formulation is a suspension formulation. Suitable forms of dexamethasone include dexamethasone alcohol (alcohol form of dexamethasone), dexamethasone acetate and dexamethasone phosphate. Dexamethasone alcohol is the preferred form of dexamethasone. The average particle size (mean volume basis) of the dexamethasone ingredient should be less than 10 μm to avoid irritation or discomfort The average particle size is preferably less than 6 μm and most preferably less than 3 μm. Dexamethasone particles can be sized using known techniques, such as ball-milling, microfluidization and sonication. The ciprofloxacin ingredient can be any otically acceptable form such that the ciprofloxacin ingredient is in solution in the final formulation. A preferred form of ciprofloxacin is ciprofloxacin hydrochloride, monohydrate.
- The dexamethasone ingredient will comprise about 0.01-0.5% and the ciprofloxacin ingredient will comprise about 0.1-0.4% of the aqueous suspension formulations administered according to the present invention. The preferred amounts of dexamethasone and ciprofloxacin in the formulations used in the present invention are 0.1% and 0.3%, respectively.
- In addition to the active agents, the suspension formulations used in the present invention contain a tonicity agent. The tonicity agent may be ionic (e.g., NaCl) or nonionic (e.g., mannitol). The tonicity agent is preferably NaCl. The amount of NaCl will depend on the desired tonicity for the final formulation, but will generally range from 0.1-0.9%. The suspension formulations of the present invention preferably contain an amount of tonicity agent sufficient to cause the formulations to have an osmolality of about 250-350 mOsm.
- The suspension formulations also contain a nonionic polymer as a suspending agent. Many otically acceptable nonionic polymers are known. These polymers include hydroxyethyl cellulose; hydroxypropylmethyl cellulose; methyl cellulose; carboxymethyl cellulose; polyvinyl pyrrolidone and polyvinyl alcohol. The preferred nonionic polymer is hydroxyethyl cellulose. The nonionic polymer will be present in the formulations of the present invention in an amount of about 0.1-0.5%. In the case of hydroxyethyl cellulose, the preferred concentration of nonionic polymer is 0.2%.
- The formulations of the present invention also contain a nonionic surfactant in an amount from about 0.01-0.2%. Many otically acceptable nonionic surfactants are known. Suitable nonionic surfactants include tyloxapol; polyoxyethylene sorbitan esters, such as polysorbate 20, polysorbate 60, and polysorbate 80; polyethoxylated castor oils, such as Cremaphor EL; polyethoxylated hydrogenated castor oils, such as HCO-40; and poloxamers. The preferred surfactant is tyloxapol.
- If desired, the formulations may contain a quaternary ammonium halide as a preservative. Suitable quaternary ammonium halides include polyquaternium-1 and benzalkonium halides. Preferred benzalkonium halides are benzalkonium chloride (“BAC”) and benzalkonium bromide. In general, the amount of the preservative ingredient will range from about 0.005-0.3%. In the preferred case where the preservative is BAC, it is preferably present at a concentration of 0.01%.
- If desired, a chelating agent may also be present in the suspension formulations used in the methods of the present invention. Suitable chelating agents include edetate disodium (“EDTA”); edetate trisodium; edetate tetrasodium; and diethyleneamine pentaacetate. Most preferred is EDTA. The chelating agent, if any, will typically be present in an amount from about 0.001-0.1%. In the case of EDTA, the chelating agent is preferably present at a concentration of 0.01%.
- In the case of preserved or multi-dose formulations, the suspension formulations of the present invention may contain boric acid in an amount from 0.1-1.5%.
- The formulations administered according to the present invention have a pH from 3-6, preferably 4.5. pH can be adjusted with NaOH/HCl. The preferred buffering system for these formulations is a combination of sodium acetate and acetic acid. The concentration of sodium acetate will generally range from 0.015-0.06%, and will preferably be about 0.03%. The concentration of acetic acid will generally range from 0.02-0.08, and will preferably be about 0.04%.
- Though physicians may prescribe other dosing regimens depending on a number of factors including the severity of the OM, the age and weight of the patient, etc., the ciprofloxacin/dexamethasone combination products administered according to the present invention will generally be administered twice a day. Each administration will typically involve placing 3-4 drops (with a typical drop volume of 30-35 μL) of the suspension product in the affected ear. Preferably, the patient will pump the tragus of the affected ear to force the administered product through the opening in the tympanic membrane and to the site of the infection/inflammation in the middle ear.
- In one embodiment, the present invention relates to a ciprofloxacin/dexamethasone aqueous suspension composition that is packaged with directions for use that indicate the composition may be used to treat otitis media in patients with an open tympanic membrane. As used herein, “directions for use” includes information contained in product labeling, package inserts and cartons or other packaging materials that accompany the ciprofloxacin/dexamethasone aqueous suspension composition of the present invention.
- The following examples are intended to illustrate, but not limit, the present invention.
-
A B C D E Ingredients % (w/w) % (w/w) % (w/w) % (w/w) % (w/w) Ciprofloxacin HCl, 0.35* 0.35 0.35 0.35 0.35 Monohydrate Dexamethasone Alcohol 0.1 0.1 0.1 0.1 0.1 Hydroxyethyl Cellulose 0.2 0.2 0.2 0.2 0.2 Benzalkonium Chloride 0.01 0.01 0.01 0.01 0.01 Sodium Acetate (Trihydrate) 0.03 0.03 0.03 0.03 0.03 Acetic Acid 0.04 0.04 0.04 0.04 0.04 Sodium Chloride 0.25 0.25 0.80 0.53 — Edetate Disodium 0.01 0.01 0.01 0.01 0.01 Tyloxapol 0.05 0.05 0.05 0.05 0.05 Glycerin 1.5 — — — 2.35 Boric Acid — — — 0.6 — NaOH/HCl q.s. pH q.s. pH q.s. pH q.s. pH q.s. pH 4.5 ± 0.2 4.5 ± 0.2 4.5 ± 0.2 4.5 ± 0.2 4.5 ± 0.2 Purified Water q.s. 100 q.s. 100 q.s. 100 q.s. 100 q.s. 100 Osmolality (mOsm) 272 99 274 286 290 - Formulations A-E were made using the following method:
- (1) For a formulation batch size of 500 ml, form a slurry by combining 75 g of 3 mm zirconium beads, 12 g of tyloxapol 1.0% stock solution and 0.5 g dexamethasone alcohol in a 30 ml polypropylene milling bottle (approx. 48% of the final batch requirement of tyloxapol is used);
- (2) steam sterilize (autoclave) the slurry, including beads;
- (3) aseptically ball mill the sterilized slurry for 18 hrs at 50 to 55 rpm;
- (4) prepare an aqueous solution containing the remaining requirement of tyloxapol and the required amounts of all remaining ingredients (e.g., in the case of Formulation D, the remaining ingredients are ciprofloxacin hydrochloride monohydrate, benzalkonium chloride, sodium acetate, acetic acid, sodium chloride, hydroxyethylcellulose, boric acid, edetate disodium, and purified water;
- (5) steam sterilize (autoclave) the aqueous solution prepared in step (4);
- (6) combine the sterile slurry obtained in
step 3 to the sterile solution obtained instep 5 by aseptically pouring the slurry through a sterile sieve (to remove the beads) into the solution obtained instep 5; - (7) adjust the formulation weight to 80-90% of batch weight using sterile-filtered purified water;
- (8) check the final pH and adjust to pH 4.5±0.2 by sterile-filtered sodium hydroxide or hydrochloric acid, if needed; and
- (9) bring the formulation to 100% of batch weight using sterile-filtered purified water.
- An alternative method of preparing Formulations A-E, especially when the dexamethasone raw material is supplied or available already meeting the desired particle size specifications, is as follows:
- (1) dry heat sterilize the dexamethasone raw material (recommended specification: between 7-11 hrs. at 130-140° C. (internal powder temperature);
- (2) prepare a tyloxapol solution containing the batch requirement of tyloxapol in purified water;
- (3) sterilize the tyloxapol solution by passing it through a 0.2 μm filter;
- (4) aseptically combine the sterilized dexamethasone with the sterilized tyloxapol solution to form a sterile slurry and stir until homogenous;
- (5) prepare an aqueous solution containing the required amounts of the remaining ingredients (e.g., in the case of Formulation D, the remaining ingredients are ciprofloxacin hydrochloride, monohydrate benzalkonium chloride, sodium acetate, acetic acid, sodium chloride, hydroxyethylcellulose, boric acid, edetate disodium and purified water;
- (6) steam sterilize (autoclave) the aqueous solution prepared in step (5);
- (7) aseptically combine the sterile slurry prepared in step (4) with the sterilized solution prepared in step (6);
- (8) adjust the formulation weight to 80-90% of batch weight using sterile-filtered, purified water.
- (9) check the final pH and adjust to pH 4.5±0.2 by sterile-filtered sodium hydroxide or hydrochloric acid, if needed; and
- (10) bring the formulation to 100% of batch weight using sterile-filtered purified water.
- A clinical study with a primary objective of demonstrating superiority of a ciprofloxacin/dexamethasone combination product (ciprofloxacin 0.3%, dexamethasone 0.1%; Formulation D above) (“CIPRODEX”) relative to the marketed CILOXAN® single-agent (ciprofloxacin 0.3%; Alcon Laboratories, Inc.) product for time to cessation of ear pain in patients with moderate to severe acute otitis externa (AOE) was conducted. A summary of the study details for this AOE study is provided below.
Summary of AOE Study CIPRODEX (Ciprofloxacin 0.3%) Suspension vs. CILOXAN (Ciprofloxacin 0.3%) Solution vs. CORTISPORIN Suspension (Neomycin 0.35%, Polymyxin B 10,000 IU/mL, Hydrocortisone 1.0%) for Topical Treatment of patients with moderate to severe Acute Otitis Externa (AOE). Study Design: Phase III multicenter, randomized, single-blind, active controlled, parallel group study. Study Primary objectives of the study were to demonstrate: Objectives: Superiority of CIPRODEX combination relative to CILOXAN single agent for time to cessation of ear pain. Therapeutic non-inferiority of CIPRODEX combination relative to CILOXAN single agent based on clinical response at the test of cure (TOC) visit (Day 18). Therapeutic non-inferiority of CIPRODEX combination relative to CORTISPORIN combination for clinical response at the TOC visit. Therapeutic non-inferiority of CILOXAN single agent relative to CORTISPORIN combination for clinical response at the TOC visit. Patient A total of 909 patients enrolled into the study at 48 investigative sites in Population: the United States between April 1998 and May 2000. Inclusion Clinical diagnosis of moderate or severe AOE, at least one year of age, Criteria: gave informed consent, and agreed to follow study procedures. Posology: Eligible patients were treated for 7 days with three drops BID CIPRODEX (n = 305), three drops BID CILOXAN (n = 305), or four drops TID CORTISPORIN (n = 299). Study Visits: Day 1, Day 3, Day 8 (End of Therapy, EOT), and Day 18 (TOC).Clinical Patient assessment of pain and tenderness using a daily diary. Evaluation: Physician evaluation of signs and symptoms of AOE, including inflammation, tenderness, edema, and otic discharge by visit. Microbiology: Microbiology outcomes were based on presumed or confirmed bacterial eradication. Efficacy Cessation of ear pain was defined as the first day where the patient dairy Criteria: pain score was zero, with no analgesics used in the prior 24 hours, and the ear pain score remained zero for all subsequent entries. Physician's assessment of clinical response of the patient at TOC on a 4-point scale (0 = cured, 1 = improved, 2 = no change, 3 = worse). Safety Based on the frequency and incidence of adverse events reported. Evaluation: Overall Time to cessation of pain is not different between CIPRODEX and Conclusions: CILOXAN treatments (i.e., no contribution of elements). CIPRODEX is non-inferior to CILOXAN for clinical cures and microbiological eradication. CIPRODEX produces more clinical cures than CORTISPORIN and is non-inferior for microbiological eradication. CILOXAN is superior to CORTISPORIN for clinical response in culture positive patients, and non-inferior for microbial eradication. CIPRODEX and CILOXAN are safe and well tolerated in pediatric and adult patients with AOE. - Time to no pain was evaluated for CIPRODEX and CILOXAN, with the results shown in Table 1 and FIG. 1. These results show the average number of days to cessation of ear pain for the “modified intent-to-treat” (“MITT”) population of the study. MITT is a term of art in the clinical sciences. For this study, the MITT population is defined as the population that received study drug, met inclusion criteria and was culture positive for bacteria on Day 1. The MITT population for this study comprised 267 patients for CIPRODEX and 261 patients for CILOXAN.
TABLE 1 MITT: Time to No Pain (in days) Treatment Mean Median CIPRODEX 6.8* 5.0 CILOXAN 6.3 5.0 - Data obtained in this AOE study demonstrate that time to cessation of ear pain was not different between CIPRODEX and CILOXAN, and therefore, no contribution of elements was shown for CIPRODEX. These results show a slight advantage for CILOXAN (6.8 days) over CIPRODEX (6.3 days) in average time to no otorrhea, but the differences were not statistically significant (p-value=0.29).
- A clinical study with a primary objective of showing therapeutic superiority of CIPRODEX (Formulation D above) relative to CILOXAN for cessation of otorrhea (ear discharge) in tympanostomy tube patients with Acute Otitis Media (AOM) was conducted. A summary of the study details for this OM study is provided below.
Summary of AOM Study Safety and Efficacy of Topical CIPRODEX (Ciprofloxacin 0.3%, Dexamethasone 0.1%) Suspension Compared to CILOXAN (Ciprofloxacin 0.3%) Solution in the Treatment of Acute Otitis Media with Tympanostomy Tubes (AOMT) Study Design: Phase II multicenter, randomized, evaluator-blind, active controlled, parallel group study. Study The study objectives were to: Objectives: Demonstrate therapeutic superiority of CIPRODEX combination relative to CILOXAN single agent for cessation of otorrhea, and to Evaluate the efficacy and safety of topical CIPRODEX Suspension in AOMT patients Patient A total of 201 patients enrolled into the study at 21 investigative sites in Population: the United States between March 2000 and January 2001. Inclusion Pediatric patients (6 months to 12 years) with a patent tympanostomy Criteria: tube and clinically diagnosed with acute otitis media with otorrhea that is visible by the parent/guardian of 3 weeks or less duration. Posology: Eligible patients were treated for 7 days with BID CIPRODEX (n = 103) or 7 days with BID CILOXAN (n = 98). Study Visits: Day 1, Day 3, Day 8 (End of Therapy, EOT), and Day 14 (Test of Cure,TOC). Clinical Twice daily patient assessment of cessation of otorrhea using a daily Evaluation: diary. Physician evaluation of signs and symptoms of AOMT, including presence of otorrhea, characteristics of otorrhea, presence of granulation tissue, tube patency, and overall clinical response by visit. Microbiology: Microbiology outcomes were based on presumed or confirmed bacterial eradication. Efficacy Cessation of otorrhea was defined as ending on the first day on which Criteria: the otorrhea is absent and remains absent for all subsequent diary entries. Physician's assessment of clinical response of the patient at TOC on a 4-point scale (0 = resolved, 1 = improved, 2 = no change, 3 = worse). Safety Based on the frequency and incidence of adverse events reported. Evaluation: Overall CIPRODEX has a statistically significantly shorter Time to Conclusions: Cessation of Otorrhea when compared to CILOXAN (using Log-Rank test of equality over strata). CIPRODEX is statistically significantly more effective than CILOXAN for Physician's Clinical Impression at the Day 3 Visit, butnot at the Day 8 or Day 14 Visits (using Cochran-Mantel-HaenszelRank Scores Test). No statistically significant differences were detected between CIPRODEX and CILOXAN for Microbiological Eradication Rates at the Test of Cure Visit (using Fisher's Exact Test). CIPRODEX and CILOXAN are safe and well tolerated in pediatric with AOMT. - The results of this study for the MITT population are presented in Table 2 and FIG. 2. For this study, the MITT population is defined as the population that received study drug, met inclusion criteria, participated in at least one on-therapy visit, and was culture positive for bacteria on Day 1. The MITT population for this study comprised 87 patients for CIPRODEX and 80 patients for CILOXAN.
TABLE 2 MITT: Time to No Otorrhea (in days) Treatment Mean Median Std. N Min. Max. CIPRODEX 4.22* 4 2.04 87 2 10 CILOXAN 5.31 5 1.94 80 2 10 - The results of this OM demonstrate a clinically and statistically significant difference in the time to cessation of otorrhea for CIPRODEX-treated patients (4.03 days) compared to CILOXAN-treated patients (5.06 days), approximately a 20% reduction in time to no otorrhea. In this study, contribution of elements for CIPRODEX was shown.
- A clinical study comparing CIPRODEX (Formulation D above) to FLOXIN in the treatment of tympanostomy tube patients with Acute Otitis Media (AOM) was conducted. A summary of the study details for this OM study is provided below.
- Safety and Efficacy of Topical CIPRODEX Otic (Ciprofloxacin 0.3%/Dexamethason 0.1%) Suspension Compared to FLOXIN Otic (Ofloxacin 0.3%) Solution in the Treatment of Acute Otitis Media with Tympanostomy Tubes (AOMT)
- Study Design: Phase III, randomized, evaluator-masked, active-controlled, parallel-group study.
- Objectives:
- To demonstrate the non-inferiority of CIPRODEX Otic Suspension relative to FLOXIN Otic Solution in clinical and microbiological response at the test of cure (TOC) visit; and
- To evaluate the efficacy and safety of CIPRODEX Otic Suspension for the treatment of patients with acute otitis media and otorrhea with tympanostomy tubes (AOMT).
- Patient Population: Approximately 500 pediatric patients with AOMT and post-tympanostomy tube otorrhea (250/arm) were planned. A total of 599 patients were enrolled.
- Diagnosis and Main Criteria for Inclusion: Pediatric patients, from 6 months to 12 years of age, with a patent tympanostomy tube, clinically diagnosed with acute otitis media and otorrhea of 3 weeks or less duration, visible by the parent/guardian, were enrolled.
- Test Product, Dose and Mode of Administration, Batch Number(s): CIPRODEX Otic (ciprofloxacin 0.3%/dexamethasone 0.1%) Suspension; topical otic administration of 4 drops into the infected ear(s) twice daily (BID) for 7 days.
- Duration of Treatment: Patients were required to undergo treatment for either seven (7) days if randomized to receive CIPRODEX or ten (10) days if randomized to receive FLOXIN.
- Reference Therapy, Dose and Mode of Administration, Batch Number(s): FLOXIN Otic (ofloxacin 0.3%) Solution; topical otic administration of 5 drops into the infected ear(s) twice daily (BID) for 10 days.
- Criteria for Evaluation: Subsequent to the demonstration of non-inferiority, superiority analyses were conducted. Analyses for the determination of superiority were based on the data set of patients who received treatment, had a positive pre-therapy culture and met the inclusion/exclusion criteria for enrollment (modified intent-to-treat, MITT). Analyses were also conducted for the intent-to-treat (ITT), per protocol (PP) and modified per protocol (MPP) data sets.
- Efficacy: The two primary variables were (1) the clinical response at the TOC visit; those patients rated as resolved/cured by the physicians based on a 4-point scale (0=resolved/cured, 1=improved, 2=not changed, 3=worsened); and (2) the microbiological response, success or failure, at the TOC visit for patients with positive pre-therapy cultures. Secondary efficacy variables were (1) the time to cessation of otorrhea as recorded in the patient diary; and as assessed by the physician's at each visit (2) the clinical response based on a 4-point scale (0=resolved/cured, 1=improved, 2=not changed, 3=worsened); (3) the granulation tissue, based on a 4-point scale (0=none, 1=mild, 2=moderate and 3=severe); (4) the presence or absence of otorrhea; (5) the otorrhea volume based on a 4-point scale (0=absent, 1=scant, 2=moderate and 3=severe); and the color/type of otorrhea based on a 5-point scale (0=absent, 1=serous, 2=mucoid, 3=purulent, 4=sanguineous).
- Safety: The safety evaluation was conducted on all patients who were randomized into the study and received at least one dose of study drug. The safety analysis was based on the following; extent of exposure to study drug; adverse events; and audiometry examination.
- Statistical Methods: The statistical objective was to demonstrate the non-inferiority of CIPRODEX relative to FLOXIN in clinical and microbiological response at the TOC visit. Two-sided 95% confidence intervals for the difference between proportions between the two treatment groups were constructed. However, due to the lack of zero within the confidence limits, non-inferiority was demonstrated, and analyses allowed for a claim of superiority. Therefore, differences between the two treatments for clinical and microbiological response were evaluated using the Chi-square test of independence. For analyses of the secondary variables, the number and proportion of patients per response in each treatment group was presented and differences were assessed using LSMEANS (Mixed Model Analysis of Variance) or the Chi-square test of independence as appropriate. The log-rank test (Kaplan-Meier survival analysis was conducted to compare median time to cessation of otorrhea between the two treatments.
- Summary—Conclusions
- CIPRODEX Otic Suspension is superior to FLOXIN Otic Solution in clinical and microbiological response at the test of cure (TOC) visit; and
- CIPRODEX Otic Suspension is effective and safe for the treatment of pediatric patients with acute otitis media and otorrhea with tympanosotomy tubes (AOMT).
- These data demonstrate the superior effectiveness of CIPRODEX, an antibiotic-steroid combination drug, for the treatment of AOMT as shown in comparative analyses to a marketed product approved for the same indication.
- This study evaluated the efficacy and safety of CIPRODEX, an antibiotic-steroid combination product (ciprofloxacin 0.3%/dexamethasone 0.1%) compared to FLOXIN, which contains antibiotic alone (ofloxacin 0.3%). The study duration was approximately three weeks long with four scheduled visits. Conditions between the treatment groups were identical except for the study drugs and the respective dosing regimens. Both drugs were topically administered BID, however, the FLOXIN group received 5 drops per dose for 10 days (per the package insert) and the CIPRODEX group, 4 drops per dose for 7 days. Outcome differences between the two groups are therefore attributed to the differences in treatment.
- Efficacy Results:
- A total of 599 patients were evaluable for the ITT analyses, 424 for the MITT, 460 for the PP and 357 for the MPP analyses. Of the ITT data set, 62% were male, 81% were Caucasian, 41% enrolled the right ear, 36% enrolled the left ear, and 23% enrolled both ears. The mean age was 2.45 years and the mean duration of the current episode of AOMT was 4.49 days in the right ear and 4.71 days in the left ear. In primary analyses, at the TOC visit, CIPRODEX was superior to FLOXIN for clinical cures for all data sets (p≦0.0027) and for microbiological eradication for MITT and MPP data sets (p≦0.0061). Additionally, for all data sets, CIPRODEX was superior to FLOXIN for treatment failure rate (p≦0.0189). In analyses of the secondary efficacy variables, CIPRODEX was superior to FLOXIN for time to cessation of otorrhea for all data sets (p≦0.018). Clinically, this translates to the cessation of otorrhea in 20 to 33% less time for the CIPRODEX treated patients in comparison to the FLOXIN treated patients (median time of 4 days for CIPRODEX versus 5-6 days for FLOXIN). For the remaining secondary efficacy variables, improvement in clinical response, absence of otorrhea, reduction in otorrhea volume and absence of otorrhea color, CIPRODEX was superior to FLOXIN at every study visit after baseline (p≦0.0023, p≦0.0012, p≦0.0003, and p≦0.0003, respectively). Moreover, at study visits Day 11 and Day 18, CIPRODEX was superior to FLOXIN for reduction in granulation tissue (p=0.0086 and p=0.0383, respectively). These outcomes demonstrate that CIPRODEX is not only a more effective treatment for AOMT in comparison to FLOXIN, but also results in a more rapid response to treatment and resolution of the clinical signs and symptoms of AOMT relative to FLOXIN. CIPRODEX is effective in treating acute otitis media with otorrhea in tympanostomy (AOMT) patients and results in 90% patients with clinical cure, 92% patients with microbiological success and a 4-day median time to cessation of otorrhea.
- Efficacy Conclusions:
- 1. CIPRODEX is superior to FLOXIN for clinical cures at the TOC visit.
Clinical Cure Rates and 95% Confidence Intervals by Treatment Group (All Data Sets) Treatment CIPRODEX FLOXIN Clinical Cure Clinical Cure No Yes No Yes Data Set N % N % N % N % Delta Lower Upper P-valuea ITT 75 25.25 222 74.75 117 38.74 185 61.26 13.49 6.10 20.88 0.0004 MITT 43 20.67 165 79.33 78 36.11 138 63.89 15.44 6.99 23.88 0.0004 PP 28 12.07 204 87.93 50 22.73 170 77.27 10.66 3.71 17.60 0.0027 MPP 18 10.00 162 90.00 37 21.76 133 78.24 11.76 4.17 19.36 0.0025 - 2. CIPRODEX is superior to FLOXIN for microbiological eradication at the TOC visit.
Microbiological Eradication Rates and 95% Confidence Intervals by Treatment Group (All Data Sets) Treatment CIPRODEX FLOXIN Microbiological Microbiological Eradication Eradication Failure Success Failure Success Data Set N % N % N % N % Delta Lower Upper P-valuea ITT 128 43.10 169 56.90 154 50.99 148 49.01 7.90 −0.07 15.87 0.0529 MITT 41 19.71 167 80.29 72 33.33 144 66.67 13.62 5.33 21.91 0.0015 PP 67 28.88 165 71.12 81 36.82 139 63.18 7.94 −0.70 16.58 0.0722 MPP 15 8.33 165 91.67 31 18.24 139 81.76 9.90 2.83 16.97 0.0061 - 3. CIPRODEX is superior to FLOXIN for treatment failure rate.
Discontinuations Due to Treatment Failure by Treatment Group Treatment CIPRODEX FLOXIN Treatment Failure Treatment Failure No Yes No Yes Data Set N % N % N % N % P-value ITT 281 94.61 16 5.39 270 89.40 32 10.60 0.0189 MITT 199 95.67 9 4.33 192 88.89 24 11.11 0.0091 PP 220 94.83 12 5.17 188 85.45 32 14.55 0.0008 MPP 172 95.56 8 4.44 146 85.88 24 14.12 0.0017 - 4. CIPRODEX is superior to FLOXIN for improvement in clinical response at
Days 3, 11 and 18.Clinical Response by Treatment Group (MITT) Treatment CIPRODEX FLOXIN Visit Clinical Response N % N % P-valuea Day 3 Missing 1 0 0 0 <.000 1 Cured 64 30.92 38 17.59 Improved 130 62.80 134 62.04 Unchanged 9 4.35 35 16.20 Worse 4 1.93 9 4.17 Day 11 Missing 1 0 0 0 <.0001 Cured 174 84.06 136 62.96 Improved 25 12.08 58 26.85 Unchanged 4 1.93 12 5.56 Worse 4 1.93 10 4.63 Day 18 Missing 1 0 0 0 0.0023 Cured 174 84.06 153 70.83 Improved 20 9.66 38 17.59 Unchanged 6 2.90 12 5.56 Worse 7 3.38 13 6.02 - 5. CIPRODEX is superior to FLOXIN for time to cessation of otorrhea.
Time to Cessation of Otorrhea by Treatment Group (MITT) Treatment CIPRODEX FLOXIN P-valuea Mean 6.02 7.10 0.0204 Median 4.00 5.00 Std 4.87 4.68 N 208 216 Min 2 2 Max 21 21 - 6. CIPRODEX is superior to FLOXIN for absence of otorrhea at
Days 3, 11 and 18.Presence/Absence of Otorrhea by Treatment Group (MITT) Treatment CIPRODEX FLOXIN Visit Otorrhea N % N % P-valuea Day 1 Present 208 100.00 216 100.00 Day 3Absent 67 32.21 40 18.52 0.0012 Present 141 67.79 176 81.48 Day 11 Absent 176 84.62 137 63.43 <.0001 Present 32 15.38 79 36.57 Day 18 Missing 1 0 0 0 0.0004 Absent 176 85.02 153 70.83 Present 31 14.98 63 29.17 - 7. CIPRODEX is superior to FLOXIN for reduction in granulation tissue at Days 11 and 18.
Granulation Tissue by Treatment Group (MITT) Treatment CIPRODEX FLOXIN Visit Granulation Tissue N % N % P-valuea Day 1 Absent 159 76.44 175 81.02 0.3449 Mild 30 14.42 21 9.72 Moderate 15 7.21 16 7.41 Severe 4 1.92 4 1.85 Day 3Missing 1 0 0 0 0.3285 Absent 177 85.51 182 84.26 Mild 24 11.59 22 10.19 Moderate 6 2.90 10 4.63 Severe 0 0.00 2 0.93 Day 11 Missing 1 0 0 0 0.0086 Absent 198 95.65 186 86.11 Mild 8 3.86 22 10.19 Moderate 1 0.48 8 3.70 Day 18 Missing 1 0 0 0 0.0383 Absent 203 98.07 192 88.89 Mild 3 1.45 21 9.72 Moderate 1 0.48 3 1.39 - 8. CIPRODEX is superior to FLOXIN for reduction in otorrhea volume at
Days 3, 11 and 18.Volume by Treatment Group (MITT) Treatment CIPRODEX FLOXIN Visit Volume N % N % P-valuea Day 1 Scant 17 8.17 14 6.48 0.3195 Moderate 104 50.00 99 45.83 Copious 87 41.83 103 47.69 Day 3Missing 1 0 0 0 <.0001 Absent 66 31.88 39 18.06 Scant 98 47.34 84 38.89 Moderate 34 16.43 77 35.65 Copious 9 4.35 16 7.41 Day 11 Missing 1 0 0 0 <.0001 Absent 175 84.54 136 62.96 Scant 19 9.18 42 19.44 Moderate 7 3.38 26 12.04 Copious 6 2.90 12 5.56 Day 18 Missing 2 0 0 0 0.0003 Absent 175 84.95 153 70.83 Scant 14 6.80 21 9.72 Moderate 8 3.88 27 12.50 Copious 9 4.37 15 6.94 - 9. CIPRODEX is superior to FLOXIN for absence of otorrhea color and less purulent otorrhea at
Day 3, and absence of otorrhea color and less mucoid otorrhea at Days 11 and 18.Color/Type by Treatment Group (MITT) Treatment CIPRODEX FLOXIN Visit Color/Type N % N % P-valuea Day 1 Absent 0 0 0 0 b Serous 21 60.00 14 40.00 0.2301 Mucoid 100 54.64 83 45.36 0.1417 Purulent 149 46.71 170 53.29 0.0607 Sanguineous 14 48.28 15 51.72 0.8335 Day 3Absent 67 63.21 39 36.79 0.0003 Serous 55 48.67 58 51.33 0.8593 Mucoid 63 43.75 81 56.25 0.2244 Purulent 36 38.71 57 61.29 0.0461 Sanguineous 1 14.29 6 85.71 0.1244 Day 11 Absent 176 56.23 137 43.77 0.0000 Serous 12 34.29 23 65.71 0.0770 Mucoid 7 15.91 37 84.09 0.0000 Purulent 14 40.00 21 60.00 0.2879 Sanguineous 0 0.00 3 100.00 0.2488 Day 18 Absent 176 53.50 153 46.50 0.0002 Serous 8 44.44 10 55.56 0.7183 Mucoid 7 18.42 31 81.58 0.0001 Purulent 18 41.86 25 58.14 0.3510 Sanguineous 0 0.00 2 100.00 0.4992 - Safety Results:
- The safety of CIPRODEX and FLOXIN was evaluated in 599 pediatric patients with acute otitis media with tympanostomy tubes. No serious adverse events related to therapy were reported during this study. Seventy-eight patients (CIPRODEX: 32; FLOXIN: 46) were discontinued from the study due to adverse events, of which 76 were due to treatment-unrelated events. Adverse events in the overall safety population were all nonserious with the exception of three reports (abdominal pain, pneumonia, cellulitis), were generally mild to moderate, usually resolved with or without treatment, and generally did not interrupt patient continuation in the study. Similar types of otic and nonotic adverse events were noted in the infant and toddler population and the children population for CIPRODEX and FLOXIN. There were no trends observed in the analysis of adverse events according to age category either within or between CIPRODEX and FLOXIN treatment groups. Only three patients in the adolescent population were enrolled, and none of the adolescents reported adverse events.
- Audiometry testing was performed to further assess the safety of CIPRODEX in the pediatric population. No clinically relevant or statistically significant (p=0.3863) difference in mean change of speech reception threshold (SRT) from baseline was observed between CIPRODEX and FLOXIN, and no clinically relevant decrease in hearing from baseline was observed with CIPRODEX or FLOXIN, based upon an assessment of bone and air conduction audiometry parameters.
- CIPRODEX administered twice daily in the affected ear(s) is safe and well tolerated in pediatric patients with acute otitis media with tympanostomy tubes, based upon a review of adverse events and an assessment of audiometry parameters.
- Safety Conclusions:
- 1. CIPRODEX administered twice daily in the affected ear(s) is safe and well tolerated in pediatric patients with acute otitis media with tympanostomy tubes, based upon a review of adverse events and an assessment of audiometry parameters.
- 2. Adverse events in the overall safety population were all nonserious with the exception of three reports (abdominal pain, pneumonia, cellulitis), were generally mild to moderate, usually resolved with or without treatment, and generally did not interrupt patient continuation in the study.
- 3. No clinically relevant or statistically significant difference in mean change of speech recognition threshold (SRT) from baseline was observed between CIPRODEX and FLOXIN.
- 4. No clinically relevant decrease in hearing from baseline was observed with CIPRODEX or FLOXIN, based upon an assessment of bone and air conduction audiometry parameters.
- The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Claims (11)
1. A method of treating a middle ear infection in a human patient comprising the steps of:
(a) diagnosing the patient as having otitis media and an open tympanic membrane in at least one ear; and
(b) topically applying into the ear canal of the patient's ear an aqueous suspension composition containing a combination of ciprofloxacin and dexamethasone.
2. The method of claim 1 wherein the aqueous suspension composition comprises
a) 0.01-0.5% (wt.) dexamethasone;
b) 0.1-0.4% (wt.) ciprofloxacin;
c) a tonicity agent consisting essentially of NaCl in an amount sufficient to cause the composition to have an osmolality of about 250-350 mOsm;
d) 0.1-0.5% (wt.) of a nonionic polymer;
e) 0.01-0.2% (wt.) of a nonionic surfactant; and
f) a buffer,
wherein the composition has a pH from about 3-5.
3. The method of claim 1 wherein the dexamethasone is dexamethasone alcohol and the ciprofloxacin is ciprofloxacin hydrochloride, monohydrate.
4. The method of claim 1 wherein the aqueous suspension composition contains 0.1% (wt.) dexamethasone and 0.3% (wt.) ciprofloxacin.
5. The method of claim 4 wherein three or four drops of the aqueous suspension composition are administered to the patient's ear twice a day, wherein each drop is 30-35 μL.
6. The method of claim 1 wherein the aqueous suspension composition consists essentially of
a) 0.1% (wt.) dexamethasone alcohol;
b) 0.35% (wt.) ciprofloxacin hydrochloride, monohydrate;
c) NaCl in an amount sufficient to cause the composition to have an osmolality of about 250-350 mOsm;
d) 0.2% (wt.) hydroxyethyl cellulose;
e) 0.05% (wt.) tyloxapol;
f) a buffer comprising sodium acetate and acetic acid;
g) 0.01% (wt.) benzalkonium chloride;
h) 0.01% (wt.) edetate disodium;
i) 0.6% (wt.) boric acid; and
wherein the composition has a pH of about 4.5.
7. The method of claim 1 wherein the method further comprises the step of pumping the tragus to force the aqueous suspension composition through the open tympanic membrane and into the middle ear.
8. The method of claim 1 wherein the dexamethasone has an average particle size on a mean volume basis of less than 3 μm.
9. The method of claim 1 wherein the otitis media is acute otitis media.
10. The method of claim 1 wherein the otitis media is chronic supprative otitis media.
11. The method of claim 1 wherein the aqueous suspension composition containing a combination of ciprofloxacin and dexamethasone is packaged with directions for use that indicate the composition may be used to treat otitis media in patients with an open tympanic membrane.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/243,341 US20030139382A1 (en) | 2001-09-21 | 2002-09-13 | Method of treating middle ear infections |
US10/946,792 US20050059674A1 (en) | 2001-09-21 | 2004-09-22 | Method of treating middle ear infections |
US12/119,185 US20080214513A1 (en) | 2001-09-21 | 2008-05-12 | Method of treating middle ear infections |
US12/357,697 US8846650B2 (en) | 2001-09-21 | 2009-02-13 | Method of treating middle ear infections |
US14/468,257 US9149486B2 (en) | 2001-09-21 | 2014-08-25 | Method of treating middle ear infections |
US14/838,637 US9345714B2 (en) | 2001-09-21 | 2015-08-28 | Method of treating middle ear infections |
US15/142,225 US9402805B1 (en) | 2001-09-21 | 2016-04-29 | Method of treating middle ear infections |
US15/223,338 US20160361324A1 (en) | 2001-09-21 | 2016-07-29 | Method of treating middle ear infections |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32395101P | 2001-09-21 | 2001-09-21 | |
US10/243,341 US20030139382A1 (en) | 2001-09-21 | 2002-09-13 | Method of treating middle ear infections |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/946,792 Division US20050059674A1 (en) | 2001-09-21 | 2004-09-22 | Method of treating middle ear infections |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030139382A1 true US20030139382A1 (en) | 2003-07-24 |
Family
ID=23261416
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/243,341 Abandoned US20030139382A1 (en) | 2001-09-21 | 2002-09-13 | Method of treating middle ear infections |
US10/946,792 Abandoned US20050059674A1 (en) | 2001-09-21 | 2004-09-22 | Method of treating middle ear infections |
US12/119,185 Abandoned US20080214513A1 (en) | 2001-09-21 | 2008-05-12 | Method of treating middle ear infections |
US12/357,697 Active 2025-06-04 US8846650B2 (en) | 2001-09-21 | 2009-02-13 | Method of treating middle ear infections |
US14/468,257 Expired - Fee Related US9149486B2 (en) | 2001-09-21 | 2014-08-25 | Method of treating middle ear infections |
US14/838,637 Expired - Fee Related US9345714B2 (en) | 2001-09-21 | 2015-08-28 | Method of treating middle ear infections |
US15/142,225 Expired - Fee Related US9402805B1 (en) | 2001-09-21 | 2016-04-29 | Method of treating middle ear infections |
US15/223,338 Abandoned US20160361324A1 (en) | 2001-09-21 | 2016-07-29 | Method of treating middle ear infections |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/946,792 Abandoned US20050059674A1 (en) | 2001-09-21 | 2004-09-22 | Method of treating middle ear infections |
US12/119,185 Abandoned US20080214513A1 (en) | 2001-09-21 | 2008-05-12 | Method of treating middle ear infections |
US12/357,697 Active 2025-06-04 US8846650B2 (en) | 2001-09-21 | 2009-02-13 | Method of treating middle ear infections |
US14/468,257 Expired - Fee Related US9149486B2 (en) | 2001-09-21 | 2014-08-25 | Method of treating middle ear infections |
US14/838,637 Expired - Fee Related US9345714B2 (en) | 2001-09-21 | 2015-08-28 | Method of treating middle ear infections |
US15/142,225 Expired - Fee Related US9402805B1 (en) | 2001-09-21 | 2016-04-29 | Method of treating middle ear infections |
US15/223,338 Abandoned US20160361324A1 (en) | 2001-09-21 | 2016-07-29 | Method of treating middle ear infections |
Country Status (19)
Country | Link |
---|---|
US (8) | US20030139382A1 (en) |
EP (1) | EP1429780B1 (en) |
JP (1) | JP2005504804A (en) |
KR (1) | KR20040035760A (en) |
CN (1) | CN1231218C (en) |
AT (1) | ATE313328T1 (en) |
AU (1) | AU2002333671B2 (en) |
BR (1) | BR0212898A (en) |
CA (1) | CA2459930C (en) |
CY (1) | CY1104988T1 (en) |
DE (1) | DE60208216T2 (en) |
DK (1) | DK1429780T3 (en) |
ES (1) | ES2250739T3 (en) |
FR (1) | FR13C0012I2 (en) |
MX (1) | MXPA04002576A (en) |
PL (1) | PL212457B1 (en) |
RU (1) | RU2295346C2 (en) |
WO (1) | WO2003026671A1 (en) |
ZA (1) | ZA200401847B (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070098679A1 (en) * | 2002-11-27 | 2007-05-03 | Regents Of The University Of Minnesota | Methods and Compositions for Applying Pharmacologic Agents to the Ear |
US20070110788A1 (en) * | 2005-11-14 | 2007-05-17 | Hissong James B | Injectable formulation capable of forming a drug-releasing device |
US20070264296A1 (en) * | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
US20070264310A1 (en) * | 2006-05-10 | 2007-11-15 | Medtronic, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
US20070264342A1 (en) * | 2006-05-10 | 2007-11-15 | Medtronic, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
US20080139545A1 (en) * | 2006-05-22 | 2008-06-12 | Won-Taek Choe | Formulation to treat ear infection |
WO2008085913A1 (en) * | 2007-01-04 | 2008-07-17 | Rib-X Pharmaceuticals, Inc. | Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections |
US20080195037A1 (en) * | 2007-02-08 | 2008-08-14 | James Britton Hissong | Film forming polymeric sealant for medical use |
US20090011045A1 (en) * | 2004-12-09 | 2009-01-08 | Bayer Healthcare Ag | Pharmaceutical for Hygienic Administration in the Ear |
US20100009952A1 (en) * | 2008-05-14 | 2010-01-14 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
US20100016450A1 (en) * | 2008-07-21 | 2010-01-21 | Otonomy, Inc. | Controlled release delivery devices for the treatment of otic disorders |
US20100086576A1 (en) * | 2008-10-06 | 2010-04-08 | Myntti Matthew F | Antimicrobial composition and methods of making and using same |
WO2010065730A2 (en) | 2008-12-05 | 2010-06-10 | Alcon Research, Ltd. | Pharmaceutical suspension |
US20100227904A1 (en) * | 2009-03-03 | 2010-09-09 | Alcon Research, Ltd. | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye |
US20100226992A1 (en) * | 2009-03-03 | 2010-09-09 | Alcon Research, Ltd. | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye |
US7976873B2 (en) | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
WO2011049958A3 (en) * | 2009-10-21 | 2011-09-09 | Otonomy, Inc. | Modulation of gel temperature of poloxamer-containing formulations |
US8784790B2 (en) | 2008-06-12 | 2014-07-22 | Medtronic Xomed, Inc. | Method for treating chronic wounds with an extracellular polymeric substance solvating system |
US20150119371A1 (en) * | 2013-10-30 | 2015-04-30 | Micro Labs Limited | Topical pharmaceutical compositions of antibiotics and steroidal anti inflammatory agents |
US9205048B2 (en) | 2008-07-21 | 2015-12-08 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
US9486405B2 (en) | 2013-08-27 | 2016-11-08 | Otonomy, Inc. | Methods for the treatment of pediatric otic disorders |
US10653133B2 (en) | 2011-05-10 | 2020-05-19 | Next Science IP Holdings Pty Ltd | Antimicrobial solid and methods of making and using same |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1231218C (en) * | 2001-09-21 | 2005-12-14 | 爱尔康公司 | Method of treating middle ear infections |
KR101289115B1 (en) * | 2004-08-13 | 2013-07-23 | 엠에스디 인터내셔널 홀딩즈 게엠베하 | Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid |
US20090263345A1 (en) * | 2008-01-28 | 2009-10-22 | Foresight Biotherapeutics, Inc. | Otic compositions for the treatment of infections of the internal and external ear in mammals |
JP5839189B2 (en) * | 2008-07-21 | 2016-01-06 | オトノミ—,インク. | Controlled release antimicrobial compositions and methods for the treatment of ear disorders |
WO2010143186A1 (en) * | 2009-06-08 | 2010-12-16 | Otic Pharma Ltd. | Otic foam formulations |
CA2896429A1 (en) | 2012-12-26 | 2014-07-03 | Otic Pharma Ltd. | Foamable otic pharmaceutical compositions |
WO2016004231A1 (en) | 2014-07-03 | 2016-01-07 | Otonomy, Inc. | Sterilization of ciprofloxacin composition |
US9393243B1 (en) * | 2015-07-14 | 2016-07-19 | Nilesh Parikh | Topical Ciprofloxacin compositions |
WO2018053173A1 (en) | 2016-09-16 | 2018-03-22 | Otonomy, Inc. | Otic gel formulations for treating otitis externa |
IT201900005280A1 (en) * | 2019-04-05 | 2020-10-05 | Ntc S R L | Otological composition |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3134718A (en) * | 1963-12-12 | 1964-05-26 | Schering Corp | Pregna-1,4-dienes and compositions containing same |
US4670444B1 (en) * | 1980-09-03 | 1999-02-09 | Bayer Ag | and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds |
US5223493A (en) * | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
US4686214A (en) * | 1985-10-30 | 1987-08-11 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
DE3704907A1 (en) * | 1987-02-17 | 1988-08-25 | Bayer Ag | TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS |
WO1990001933A1 (en) * | 1988-08-26 | 1990-03-08 | Alcon Laboratories, Inc. | Combination of quinolone antibiotics and steroids for topical ophthalmic use |
DK0604570T3 (en) * | 1991-09-17 | 1998-09-14 | Alcon Lab Inc | Preparations containing quinolone antibiotics and polystyrene sulfonate |
ES2065846B1 (en) | 1993-04-20 | 1995-10-01 | Cusi Lab | PHARMACEUTICAL FORMULATION BASED ON A STEROID OR NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTIBIOTIC BELONGING TO THE GIRASE DNA INHIBITORS GROUP FOR ITS TOPICAL OPHTHALMIC USE. |
US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
ES2078175B1 (en) | 1993-12-31 | 1996-10-16 | Cusi Lab | PHARMACEUTICAL FORMULATION CONTAINING CLOBETASONE AND TOBRAMYCIN AND ITS APPLICATIONS. |
ES2079320B1 (en) * | 1994-05-17 | 1996-10-16 | Cusi Lab | OPHTHALMIC DISSOLUTION BASED ON A DICLOFENACO AND TOBRAMYCIN AND ITS APPLICATIONS. |
US5843930A (en) * | 1995-06-06 | 1998-12-01 | Bayer Corporation | Method of treating otitis with ciprofloxacin-hydrocortisone suspension |
CN1137685C (en) | 1995-06-06 | 2004-02-11 | 拜尔公司 | Non-irritation, non-sensitizing non-ototoxic otic antibacterial compositions |
DE19524691A1 (en) * | 1995-07-06 | 1997-01-09 | Liedtke Pharmed Gmbh | Method and composition of topical therapy for inner ear and labyrinth symptoms |
KR100508227B1 (en) | 1997-03-14 | 2006-03-23 | 센주 세이야꾸 가부시키가이샤 | Aqueous suspension of loteprednol etabonate |
AR020660A1 (en) | 1998-09-30 | 2002-05-22 | Alcon Lab Inc | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF EYES, EARS AND NOSE |
AU6275999A (en) | 1998-09-30 | 2000-04-17 | Alcon Laboratories, Inc. | Antibiotic compositions for treatment of the eye, ear and nose |
US6395746B1 (en) | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
AR020661A1 (en) | 1998-09-30 | 2002-05-22 | Alcon Lab Inc | A PHARMACEUTICAL COMPOSITION TOPICA OFTALMICA, OTICA OR NASAL AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
EP1214056B1 (en) * | 1999-09-24 | 2003-10-29 | Alcon Inc. | Topical suspension formulations containing ciprofloxacin and dexamethasone |
CN1231218C (en) * | 2001-09-21 | 2005-12-14 | 爱尔康公司 | Method of treating middle ear infections |
-
2002
- 2002-09-13 CN CNB028183002A patent/CN1231218C/en not_active Expired - Lifetime
- 2002-09-13 CA CA002459930A patent/CA2459930C/en not_active Expired - Lifetime
- 2002-09-13 EP EP02799587A patent/EP1429780B1/en not_active Expired - Lifetime
- 2002-09-13 KR KR10-2004-7003637A patent/KR20040035760A/en not_active Application Discontinuation
- 2002-09-13 RU RU2004111984/14A patent/RU2295346C2/en active
- 2002-09-13 US US10/243,341 patent/US20030139382A1/en not_active Abandoned
- 2002-09-13 AT AT02799587T patent/ATE313328T1/en active
- 2002-09-13 DK DK02799587T patent/DK1429780T3/en active
- 2002-09-13 DE DE60208216T patent/DE60208216T2/en not_active Expired - Lifetime
- 2002-09-13 PL PL369205A patent/PL212457B1/en unknown
- 2002-09-13 ES ES02799587T patent/ES2250739T3/en not_active Expired - Lifetime
- 2002-09-13 JP JP2003530306A patent/JP2005504804A/en active Pending
- 2002-09-13 WO PCT/US2002/029373 patent/WO2003026671A1/en active IP Right Grant
- 2002-09-13 MX MXPA04002576A patent/MXPA04002576A/en active IP Right Grant
- 2002-09-13 BR BR0212898-5A patent/BR0212898A/en not_active Application Discontinuation
- 2002-09-13 AU AU2002333671A patent/AU2002333671B2/en not_active Expired
-
2004
- 2004-03-05 ZA ZA2004/01847A patent/ZA200401847B/en unknown
- 2004-09-22 US US10/946,792 patent/US20050059674A1/en not_active Abandoned
-
2006
- 2006-02-21 CY CY20061100244T patent/CY1104988T1/en unknown
-
2008
- 2008-05-12 US US12/119,185 patent/US20080214513A1/en not_active Abandoned
-
2009
- 2009-02-13 US US12/357,697 patent/US8846650B2/en active Active
-
2013
- 2013-02-21 FR FR13C0012C patent/FR13C0012I2/en active Active
-
2014
- 2014-08-25 US US14/468,257 patent/US9149486B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 US US14/838,637 patent/US9345714B2/en not_active Expired - Fee Related
-
2016
- 2016-04-29 US US15/142,225 patent/US9402805B1/en not_active Expired - Fee Related
- 2016-07-29 US US15/223,338 patent/US20160361324A1/en not_active Abandoned
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9592196B2 (en) | 2002-11-27 | 2017-03-14 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
US8734836B2 (en) * | 2002-11-27 | 2014-05-27 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
US20070098679A1 (en) * | 2002-11-27 | 2007-05-03 | Regents Of The University Of Minnesota | Methods and Compositions for Applying Pharmacologic Agents to the Ear |
US20090011045A1 (en) * | 2004-12-09 | 2009-01-08 | Bayer Healthcare Ag | Pharmaceutical for Hygienic Administration in the Ear |
US20070110788A1 (en) * | 2005-11-14 | 2007-05-17 | Hissong James B | Injectable formulation capable of forming a drug-releasing device |
US20070264296A1 (en) * | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
US8691288B2 (en) | 2006-05-10 | 2014-04-08 | Medtronic, Inc. | Gallium-containing sealant for medical use |
US7959943B2 (en) | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
US7993675B2 (en) | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
US20090258086A1 (en) * | 2006-05-10 | 2009-10-15 | Medtronic Xomed, Inc. | Biofilm extracellular polysaccharide solvating system |
US7976873B2 (en) | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
US7976875B2 (en) | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Biofilm extracellular polysaccharide solvating system |
US20070264342A1 (en) * | 2006-05-10 | 2007-11-15 | Medtronic, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
US20070264310A1 (en) * | 2006-05-10 | 2007-11-15 | Medtronic, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
US20080139545A1 (en) * | 2006-05-22 | 2008-06-12 | Won-Taek Choe | Formulation to treat ear infection |
WO2008085913A1 (en) * | 2007-01-04 | 2008-07-17 | Rib-X Pharmaceuticals, Inc. | Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections |
US8088095B2 (en) | 2007-02-08 | 2012-01-03 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
US20080195037A1 (en) * | 2007-02-08 | 2008-08-14 | James Britton Hissong | Film forming polymeric sealant for medical use |
US9119896B2 (en) | 2007-02-08 | 2015-09-01 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
US20100009952A1 (en) * | 2008-05-14 | 2010-01-14 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
RU2469726C2 (en) * | 2008-05-14 | 2012-12-20 | Отономи, Инк. | Corticosteroid-based composition with controlled release for treatment of ear diseases |
US9511020B2 (en) | 2008-05-14 | 2016-12-06 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
US20110008456A1 (en) * | 2008-05-14 | 2011-01-13 | Otonomy, Inc. | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders |
US8828980B2 (en) | 2008-05-14 | 2014-09-09 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
US8030297B2 (en) | 2008-05-14 | 2011-10-04 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders |
WO2009139924A3 (en) * | 2008-05-14 | 2010-04-01 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
US9744126B2 (en) | 2008-05-14 | 2017-08-29 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
CN102026623B (en) * | 2008-05-14 | 2013-08-14 | 奥德纳米有限公司 | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
US8546363B2 (en) | 2008-05-14 | 2013-10-01 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
US8658626B2 (en) | 2008-05-14 | 2014-02-25 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
US8680082B2 (en) | 2008-05-14 | 2014-03-25 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
US8680083B2 (en) | 2008-05-14 | 2014-03-25 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
US9700344B2 (en) | 2008-06-12 | 2017-07-11 | Medtronic Xomed, Inc. | Method for treating chronic wounds with an extracellular polymeric substance solvating system |
US8784790B2 (en) | 2008-06-12 | 2014-07-22 | Medtronic Xomed, Inc. | Method for treating chronic wounds with an extracellular polymeric substance solvating system |
US9205048B2 (en) | 2008-07-21 | 2015-12-08 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
US9603796B2 (en) | 2008-07-21 | 2017-03-28 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
US11369566B2 (en) | 2008-07-21 | 2022-06-28 | Alk-Abelló, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
US10772828B2 (en) | 2008-07-21 | 2020-09-15 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
US9867778B2 (en) | 2008-07-21 | 2018-01-16 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
US20100016450A1 (en) * | 2008-07-21 | 2010-01-21 | Otonomy, Inc. | Controlled release delivery devices for the treatment of otic disorders |
US9233068B2 (en) | 2008-07-21 | 2016-01-12 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders |
US8940792B2 (en) | 2008-10-06 | 2015-01-27 | Next Science, Llc | Antimicrobial composition and methods for using same |
US20100086576A1 (en) * | 2008-10-06 | 2010-04-08 | Myntti Matthew F | Antimicrobial composition and methods of making and using same |
US9707173B2 (en) | 2008-12-05 | 2017-07-18 | Alcon Research, Ltd. | Pharmaceutical suspension |
WO2010065730A2 (en) | 2008-12-05 | 2010-06-10 | Alcon Research, Ltd. | Pharmaceutical suspension |
US20100144719A1 (en) * | 2008-12-05 | 2010-06-10 | Kabra Bhagwati P | Pharmaceutical suspension |
US20100227904A1 (en) * | 2009-03-03 | 2010-09-09 | Alcon Research, Ltd. | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye |
US20100226992A1 (en) * | 2009-03-03 | 2010-09-09 | Alcon Research, Ltd. | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye |
US8912236B2 (en) | 2009-03-03 | 2014-12-16 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
WO2011049958A3 (en) * | 2009-10-21 | 2011-09-09 | Otonomy, Inc. | Modulation of gel temperature of poloxamer-containing formulations |
US10653133B2 (en) | 2011-05-10 | 2020-05-19 | Next Science IP Holdings Pty Ltd | Antimicrobial solid and methods of making and using same |
US9486405B2 (en) | 2013-08-27 | 2016-11-08 | Otonomy, Inc. | Methods for the treatment of pediatric otic disorders |
US20150119371A1 (en) * | 2013-10-30 | 2015-04-30 | Micro Labs Limited | Topical pharmaceutical compositions of antibiotics and steroidal anti inflammatory agents |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9402805B1 (en) | Method of treating middle ear infections | |
AU2002333671A1 (en) | Method of treating middle ear infections | |
EP1575597B1 (en) | Use of rimexolone in the treatment of dry eye | |
US20010034339A1 (en) | Topical suspension formulations containing ciprofloxacin and dexamethasone | |
AU2006295248A1 (en) | Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear | |
WO2013078998A1 (en) | Novel slow-releasing ophthalmic compositions comprising povidone iodine | |
US9114168B2 (en) | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug | |
US20130338126A1 (en) | Ophthalmic Suspension for Ocular Use | |
US11040004B2 (en) | Otic gel formulations for treating otitis externa | |
Nyalazi et al. | A Rare Case of Bilateral Post Intravitreal Avastin Endophthalmitis with Bilateral Good Visual Outcome–A Case Report | |
Theodosiadis et al. | Non-inferiority evaluation of preservative-free latanoprost/timolol eye drops solution versus preserved latanoprost/timolol eye drops in patients with high intraocular pressure and open-angle glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALCON, INC., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WALL, G. MICHAEL;CONROY, PETER J.;REEL/FRAME:013302/0801 Effective date: 20020912 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |